Structural characterization and anti‐angiogenic properties of prostate‐specific antigen isoforms in seminal fluid

@article{Mattsson2008StructuralCA,
  title={Structural characterization and anti‐angiogenic properties of prostate‐specific antigen isoforms in seminal fluid},
  author={Johanna Sofia Margareta Mattsson and Leena Valmu and Pirjo Laakkonen and U-H. Stenman and Hannu Koistinen},
  journal={The Prostate},
  year={2008},
  volume={68}
}
The prostate produces high levels of prostate‐specific antigen (PSA), which has been shown to exert anti‐angiogenic properties and thus might slow down prostate tumor growth. It has been suggested that the protease activity of PSA is not needed for its anti‐angiogenic function. We have previously shown that seminal fluid contains both active and inactive, internally cleaved forms of PSA. The precise structural differences between these isoforms and their function are not known. 
Peptides binding to prostate‐specific antigen enhance its antiangiogenic activity
TLDR
Using phage display, peptides C4 and B2 are developed that stimulate the enzymatic activity of PSA to study whether these peptides enhance the antiangiogenic activityof PSA. Expand
Enzymatic activity of free‐prostate‐specific antigen (f‐PSA) is not required for some of its physiological activities
TLDR
Little is known about the molecular mechanism(s) involved in regulation of these processes, in particular the role of the serine‐protease enzymatic activity of PSA. Expand
Antiangiogenic properties of prostate‐specific antigen (PSA)
TLDR
Recent studies suggest that PSA exerts antiantiogenic activity related to its enzymatic activity, which might be associated with the slow growth of prostate cancer. Expand
Novel small molecule inhibitors for prostate‐specific antigen
TLDR
A chemical library was screened to find drug‐like compounds that could be used to modulate the function(s) of PSA and identified peptides that stimulate the activity of PSC. Expand
Anti‐angiogenic activity of PSA‐derived peptides
PSA is a biomarker for diagnosis and management of prostate cancer. PSA is known to have anti‐tumorigenic activities, however, the physiological role of PSA in prostate tumor progression is not wellExpand
PSA forms complexes with α1‐antichymotrypsin in prostate
TLDR
Results regarding the extent which PSA forms complexes within the prostate and whether there are differences in complex formation between normal and malignant prostatic tissue are inconsistent and limited. Expand
Development of molecules stimulating the activity of KLK3 – an update
TLDR
It may be possible to slow down the growth of prostatic tumors by enhancing the activity of Kallikrein-related peptidase-3 by developing peptides that enhance the proteolytic activity of KLK3. Expand
Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
TLDR
It is shown that PSA degrades semenogelins I and II much more efficiently than other previously identified protein substrates, e.g., fibronectin, galectin-3 and IGFBP-3. Expand
KLK-targeted Therapies for Prostate Cancer
TLDR
Although KLKs are attractive targets for prostate cancer treatment, much remains to be done before their potential can be fully elucidated, and none of these are used to treat prostate cancer. Expand
The Discovery of Compounds That Stimulate the Activity of Kallikrein‐Related Peptidase 3 (KLK3)
TLDR
Four small, drug‐like compounds with affinity for KLK3 were discovered and validated by capillary differential scanning calorimetry, and one of the compounds also stimulated the activity of KLK 3, and is therefore the first published small molecule with such an activity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo
TLDR
This work recently described anti‐angiogenic properties of PSA, a kallikrein family member with serine protease activity commonly used as a diagnostic marker for prostate cancer. Expand
Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
TLDR
Prostate‐specific antigen (PSA) targeted prodrugs are under development in the laboratory and have not been well characterized in human prostate cancer xenograft models. Expand
Separation of enzymatically active and inactive prostate‐specific antigen (PSA) by peptide affinity chromatography
TLDR
This work has identified novel PSA‐binding peptides that enhance the enzymatic activity of PSA when produced as fusion proteins as well as serine protease with highly prostate‐specific expression. Expand
Antiangiogenic activity of prostate-specific antigen.
TLDR
This is the first report that PSA may function in tumors as an endogenous antiangiogenic protein, and calls into question various strategies to inhibit the expression of PSA in the treatment of prostate cancer. Expand
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
TLDR
It is shown that prostate-specific antigen (PSA), a serine proteinase secreted by human prostate and human prostate cancer cells, is able to convert Lys-plasminogen to biologically active angiostatin-like fragments, containing kringles 1–4, by limited proteolysis of peptide bond Glu439–Ala440 in vitro. Expand
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Prostate-specific antigen (PSA) is a glycoprotein secreted by prostate epithelial cells. PSA is currently used as a marker of prostate carcinoma because high levels of PSA are indicative of a tumorExpand
Substrate specificity of prostate-specific antigen (PSA).
TLDR
The importance of secondary subsites in defining both the specificity and efficiency of cleavage suggests that substrate recognition by PSA is mediated by an extended binding site, which should facilitate the development of more sensitive activity-based assays and the design of potent inhibitors. Expand
Prostate-specific antigen.
TLDR
Determination of the proportion of free PSA has become widely used to improve the cancer specificity of PSA especially in men with PSA values in the 'grey zone' (4-10 microg/l). Expand
Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.
TLDR
A specific and sensitive method for the measurement of active PSA and using the synthetic peptide KGISSQY, which possesses a PSA-specific cleavage site, as substrate to measure proPSA in blood, which shows thatforms of PSA are a considerable fraction of free PSA in the blood of patients with increased total PSA. Expand
Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands
Prostatic acid phosphatase (PAP), prostate‐specific antigen (PSA), and β‐microseminoprotein (β‐MSP) were regularly localized immunohistochemically to the epithelium of the acini and that of the ductsExpand
...
1
2
3
4
5
...